Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE At follow-up, 8 out of 41 patients (19.5%) with MCI had progressed to dementia, 8 patients (19.5%) had improved to normal levels of cognitive functioning, 25 patients (61%) had remained stable within the MCI group. 9850913 1998
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Nine adults with DS and dementia plus four who are exhibiting declines in cognition analogous to mild cognitive impairment in the general population (MCI-DS) were compared to their pair-matched peers with DS but without dementia or MCI-DS. 18571319 2008
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE Among 200 outpatients with dementia and MCI whose NGF SNP rs6330 genotype was identified, those with A-MCI (n = 35) and early-stage AD (n = 67) were recruited and divided into three groups according to genotype (C/C: n = 58, C/T: n = 39, T/T: n = 5). 22301435 2011
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Pre-MCI subjects showed accelerated rates of progression to MCI as compared to NCI subjects, but slower rates of progression to dementia than MCI subjects. 21422909 2011
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments. 22076544 2011
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE Among 200 outpatients with dementia and MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, based on the representative BDNF functional polymorphism Val66Met. 22699449 2012
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Carriers were more likely to receive scores of 0.5 or higher on the CDR (p < 0.001), and a clinical diagnosis of either MCI or dementia (p = 0.004). 22442429 2012
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE Among 215 outpatients with dementia and MCI, 155 with mild AD (n = 108) or A-MCI (n = 47) were recruited and divided into three genotypic groups based on the representative NT-3 functional polymorphisms rs6332 and rs6489630. 23075484 2012
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE 208 participants remained normal and 60 developed cognitive decline, consistent with a diagnosis of MCI or dementia. 25212916 2014
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE CSF Apo-E levels were associated with longitudinal cognitive decline, MCI conversion to dementia, and gray matter atrophy rate in total tau/Aβ1-42 ratio and APOE genotype-adjusted analyses. 24385135 2014
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. 23375567 2014
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Although PD-MCI is a risk factor for developing Parkinson's disease dementia there is evidence to suggest that PD-MCI might consist of distinct subtypes with different pathophysiologies and prognoses. 25814509 2015
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Further comparisons with our previous cross-sectional findings indicated that telomere lengths prior to clinical decline were similar to those of other adults with Down syndrome (DS) who have not experienced clinical decline while telomere lengths following transition to MCI-DS or dementia in the current study were comparable to those of other adults with DS who have developed MCI-DS or dementia. 26593971 2016
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE In a follow-up analysis using an independent data set, we demonstrate a protective effect of this variant against risk of conversion to MCI or AD (p = 0.038) and against cognitive decline in individuals who develop dementia (p = 3.41 × 10<sup>-15</sup> ). 29130521 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE The Q mci-TR is a reliable and useful screening tool for discriminating MCI from SMC and dementia in a Turkish population. 28423938 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE A high prevalence of MCI or dementia was observed in the elderly population. 28769097 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE One hundred and seven elderly subjects with cognitive impairment (91 memory clinic patients with mild cognitive impairment [MCI] and 16 with dementia of AD type) and 55 cognitively healthy volunteers were included in this study. 29054536 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Higher stride time variability was associated with falls in older adults without dementia (CHI and each MCI subgroup) and mild non-AD dementia, whereas lower gait speed was associated with falls in all participant groups, except in mild AD dementia. 27914848 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Individuals who were married and those who were very satisfied with life are protected against the risk of developing MCI and dementia. 28269770 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE The presented approach is a valuable tool for identifying patients with dementia or MCI and for supporting the clinician in the diagnostic process, by providing an outstanding support decision tool in the diagnostics of neurodegenerative diseases. 29054264 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE In the absence of a specific phenotype, the diagnosis of MCI might identify PSP patients at greatest risk of developing dementia and should be considered further in the diagnostic assessment. 28881351 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Cognitive function was assessed using two computer-based questionnaires (touch panel-type dementia assessment scale [TDAS] and mild cognitive impairment [MCI] screen). 28345266 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Determination of YKL-40 CSF concentration may be also helpful in differentiation between types of dementia and in the distinction of patients in the stable phase of MCI from those who progressed to dementia. 28183245 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE In all cohorts, the strongest determinant for dementia development was the co-existence of RBD, MCI and orthostatic hypotension at baseline. 27911340 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 GeneticVariation disease BEFREE 150 individuals with ET (109 Normal Cognition (ET-NC group), and 30 with MCI and 11 dementia (ET-CI group)) completed self-ratings and objective assessments of memory, language, and executive functioning. 28477687 2017